Business Context and Reporting Period
Company: Eastman Kodak Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: Kodak operates three primary reportable segments: Consumer Digital Imaging Group (CDG), Film Products Group (FPG), and Graphic Communications Group (GCG). The reporting period is significantly impacted by the divestiture of the Health Group segment, classified as discontinued operations, which closed on April 30, 2007.
Key Financial Metrics
| Metric (in millions) | Q3 2007 | Q3 2006 | 9 Months 2007 | 9 Months 2006 |
|---|---|---|---|---|
| Net Sales | $2,581 | $2,595 | $7,210 | $7,575 |
| Gross Profit | $682 | $651 | $1,757 | $1,695 |
| Gross Margin | 26.4% | 25.1% | 24.4% | 22.4% |
| Net Earnings (Loss) | $37 | $(37) | $461 | $(617) |
| EPS (Diluted) | $0.13 | $(0.13) | $1.60 | $(2.15) |
| Cash and Equivalents | $1,847 | $1,102 (End of Period) | $1,847 (End of Period) | $1,102 (End of Period) |
| Long-Term Debt | $1,296 | $2,714 | $1,296 | $2,714 |
| Operating Cash Flow (9M) | $(724) million (Continuing: $(694)M; Discontinued: $(30)M) |
Note: Net earnings for the nine months ended September 30, 2007, include a significant gain from discontinued operations ($753 million) related to the sale of the Health Group.
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net profit of $37 million for Q3 2007, compared to a net loss of $37 million in Q3 2006. For the nine-month period, net earnings were $461 million versus a loss of $617 million in the prior year. This improvement is largely driven by a $980 million pre-tax gain on the sale of the Health Group (discontinued operations).
- Continuing Operations: Excluding discontinued operations, continuing operations generated a profit of $34 million in Q3 2007 compared to a loss of $83 million in Q3 2006. For the nine months, continuing operations resulted in a loss of $292 million, an improvement from a $784 million loss in the prior year.
- Revenue Trends: Consolidated net sales were flat in Q3 (-1%) and down 5% for the nine months. Digital sales grew (Q3 +12%, 9M +4%), offsetting declines in traditional film and paper products (Q3 -16%, 9M -15%).
- Debt Reduction: Long-term debt decreased significantly from $2.714 billion to $1.296 billion. The company used proceeds from the Health Group sale to fully repay approximately $1.15 billion in Secured Term Debt.
- Restructuring: Restructuring charges for Q3 2007 were $100 million (down from $108 million in Q3 2006). The 2004-2007 Restructuring Program has incurred life-to-date charges of $3.329 billion as of September 30, 2007.
Guidance, Outlook, and Risks
- Restructuring Outlook: The company expects total employment reductions under the 2004-2007 program to be in the range of 27,000 to 28,000 positions, with total charges between $3.4 billion and $3.6 billion. Expected annual cost savings from the program are estimated at $1.6 billion to $1.8 billion.
- Liquidity: Management believes cash flow from operations and asset sales will be sufficient to cover working capital, capital investment, debt reduction, and restructuring payments. The company maintains $1.086 billion in committed bank lines of credit.
- Segment Performance:
- CDG: Digital sales growth driven by cameras and kiosks; traditional sales declining.
- FPG: Significant volume declines in film capture (-32% in Q3) offset by cost reductions and favorable foreign exchange.
- GCG: Sales growth driven by digital prepress and printing solutions.
- Risks and Contingencies:
- Environmental: Accrued liabilities for environmental remediation total $140 million, primarily related to the Kodak Park site in Rochester, NY.
- Legal: Ongoing SEC informal inquiry regarding prior financial statement restatements; various patent infringement suits.
- Market: Continued secular decline in traditional film businesses and uncertainty regarding profitability in digital businesses.
- Credit Ratings: S&P affirmed Corporate Rating at B+ (Negative Outlook); Moody's affirmed Corporate Rating at B1 (Stable Outlook).
Investor Verification Checklist
- Discontinued Operations Impact: Verify the sustainability of earnings by analyzing results excluding the one-time $980 million gain from the Health Group sale.
- Continuing Operations Cash Flow: Review the $694 million net cash used in continuing operating activities for the nine months to assess liquidity pressure from core business operations.
- Restructuring Execution: Monitor the pace of severance payments and the realization of the projected $1.6 billion+ in annual cost savings.
- Traditional vs. Digital Mix: Track the rate of decline in traditional film/paper sales versus the growth rate of digital capture and printing solutions to evaluate the transition strategy.
- Debt Covenants: Confirm continued compliance with the Secured Credit Agreement covenants (Debt/EBITDA and EBITDA/Interest ratios) given the reduced debt load.